Scientists hunt for biomarkers to personalize stomach cancer treatment
NCT ID NCT05508399
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study analyzed blood and tumor tissue samples from 28 people with stomach cancer to find biological markers that predict how well immunotherapy (tislelizumab) combined with chemotherapy works before surgery. The goal was to build a model that uses RNA and other factors to forecast treatment success. Since it's an observational study, it does not test a new treatment but aims to improve future treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors predict which patients with stomach cancer will benefit most from combining immunotherapy with chemotherapy before surgery.
What could go wrong
This is a small, completed observational study (28 participants) that identifies potential biomarkers, not a treatment trial. The findings need validation in larger studies before they can guide patient care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Xijing Hospital of Digestive Diseases
Xi'an, Shaanxi, 710000, China